268 related articles for article (PubMed ID: 29218680)
1. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
Thai-Cuarto D; O'Brien CF; Jimenez R; Liang GS; Burke J
Drug Saf; 2018 Apr; 41(4):429-440. PubMed ID: 29218680
[TBL] [Abstract][Full Text] [Related]
2. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
[TBL] [Abstract][Full Text] [Related]
5. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
[TBL] [Abstract][Full Text] [Related]
6. The effects of valbenazine on tardive dyskinesia in older and younger patients.
Sajatovic M; Alexopoulos GS; Burke J; Farahmand K; Siegert S
Int J Geriatr Psychiatry; 2020 Jan; 35(1):69-79. PubMed ID: 31617235
[TBL] [Abstract][Full Text] [Related]
7. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
10. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28497864
[TBL] [Abstract][Full Text] [Related]
11. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
12. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M; Pigato G; Kane JM; Correll CU
Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
[TBL] [Abstract][Full Text] [Related]
13. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
Aggarwal S; Serbin M; Yonan C
J Comp Eff Res; 2019 Oct; 8(13):1077-1088. PubMed ID: 31464152
[No Abstract] [Full Text] [Related]
14. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.
Correll CU; Cutler AJ; Kane JM; McEvoy JP; Liang GS; O'Brien CF
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30695293
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).
Horiguchi J; Watanabe K; Kondo K; Iwatake A; Sakamoto H; Susuta Y; Masui H; Watanabe Y
Psychiatry Clin Neurosci; 2022 Nov; 76(11):560-569. PubMed ID: 36114799
[TBL] [Abstract][Full Text] [Related]
16. A long-term, open-label study of valbenazine for tardive dyskinesia.
Lindenmayer JP; Verghese C; Marder SR; Burke J; Jimenez R; Siegert S; Liang GS; O'Brien CF
CNS Spectr; 2021 Aug; 26(4):345-353. PubMed ID: 32419679
[TBL] [Abstract][Full Text] [Related]
17. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
[TBL] [Abstract][Full Text] [Related]
18. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
[TBL] [Abstract][Full Text] [Related]
20. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F; Luther K; Talreja O
Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
